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Abstract
Objectives: We analyzed whether mast cell stabilization by either ketotifen or tranilast could alter either sympathetic
or nitrergic innervation function in rat mesenteric arteries.
Methods: Electrical field stimulation (EFS)-induced contraction was analyzed in mesenteric segments from 6-month-
old Wistar rats in three experimental groups: control, 3-hour ketotifen incubated (0.1 αmol/L), and 3-hour tranilast
incubated (0.1 mmol/L). To assess the possible participation of nitrergic or sympathetic innervation, EFS contraction
was analyzed in the presence of non-selective nitric oxide synthase (NOS) inhibitor L-NAME (0.1 mmol/L), α-
adrenergic receptor antagonist phentolamine (0.1 µmol/L), or the neurotoxin 6-hydroxydopamine (6-OHDA, 1.46
mmol/L). Nitric oxide (NO) and superoxide anion (O2.-) levels were measured, as were vasomotor responses to
noradrenaline (NA) and to NO donor DEA-NO, in the presence and absence of 0.1 mmol/L tempol. Phosphorylated
neuronal NOS (P-nNOS) expression was also analyzed.
Results: EFS-induced contraction was increased by ketotifen and decreased by tranilast. L-NAME increased the
vasoconstrictor response to EFS only in control segments. The vasodilator response to DEA-NO was higher in
ketotifen- and tranilast-incubated segments, while tempol increased vasodilator response to DEA-NO only in control
segments. Both NO and O2- release, and P-nNOS expression were diminished by ketotifen and by tranilast
treatment. The decrease in EFS-induced contraction produced by phentolamine was lower in tranilast-incubated
segments. NA vasomotor response was decreased only by tranilast. The remnant vasoconstriction observed in
control and ketotifen-incubated segments was abolished by 6-OHDA.
Conclusion: While both ketotifen and tranilast diminish nitrergic innervation function, only tranilast diminishes
sympathetic innnervation function, thus they alter the vasoconstrictor response to EFS in opposing manners.
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Introduction
Arterial tone is regulated by the central nervous system,
perivascular innervation and myogenic mechanisms, as well as
by endothelial and humoral factors. Perivascular innervation
plays a principal role in the regulation of vascular tone,
specifically in certain vessels such as the mesenteric vascular
bed [1,2], where blood flow is approximately 20-30% of the
total cardiac output [3]. Inadequate mesenteric blood flow and
tissue perfusion can produce relevant haemodynamic changes
[3–5]. This regulation involves sympathetic and nitrergic
innervations (1,2), which mainly release mainly noradrenaline
(NA) or ATP from sympathetic nerve terminals [6], and nitric
oxide (NO) from nitrergic innervation [7,8].
An interaction between mast cells and nerve endings has
been observed in the gastrointestinal tract [9] and cardiac
tissue [10]. When stimulated, these cells degranulate,
subsequently releasing a variety of mediators, such as neutral
proteases, growth factors, cytokines and chemokines, as well
as vasoactive substances like serotonin, histamine,
leukotrienes and prostaglandins [11,12], which can affect
perivascular mesenteric innervation function.
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Ketotifen and tranilast are effective mast cell stabilizer
agents widely used in the management of allergic and
inflammatory disorders. Both drugs block a calcium channel
essential for mast cell degranulation, thereby stabilizing the cell
membrane[12–15]. . Additionally, ketotifen and tranilast can
also induce different additional effects apart from mast cell
stabilization, effects that could induce different alterations in
perivascular nerve function [16–18].
Based on these considerations, the aim of this study was to
analyze the possible different effects of ketotifen and tranilast
on sympathetic and nitrergic function in rat mesenteric arteries,
as well as the mechanism/s implicated.
Methods
Ethics Statement
All animals were housed in the Animal Facility of the
Universidad Autónoma de Madrid (Registration number
EX-021U) in accordance with directives 609/86 of the E.E.C.,
R.D. 233/88 of the Ministerio de Agricultura, Pesca y
Alimentación of Spain, and Guide for the Care and Use of
Laboratory Animals published by the USA National Institutes of
Health (NIH publication No. 85.23, revised 1985). The
experimental protocol was approved by the Ethics Committee
of the Universidad Autónoma de Madrid.
Animals
We used 6 month-old male Wistar rats. Rats were sacrificed
by CO2 inhalation followed by decapitation; the first branch of
the mesenteric artery was carefully dissected out, cleaned of
connective tissue and placed in Krebs–Henseleit solution
(KHS, in mmol/L : NaCl 115, CaCl2 2.5, KCl 4.6, KH2PO4 1.2,
MgSO4. 7H2O 1.2, NaHCO3 25, glucose 11.1, Na 2EDTA 0.03)
at 4°C. Some samples were immediately frozen in liquid
nitrogen and stored at -70 °C.
Perivascular mast cell detection
Mesenteric arteries were fixed in 4% formaldehyde in
phosphate buffered saline solution (PBS, pH=7.4) for 1 hour,
cryoprotected with 30% w/v sucrose in PBS (overnight),
transferred to a cryomold containing Tissue-Tek OCT
embedding medium (20 min) and then immediately frozen in
liquid nitrogen. All samples were kept at -70 °C until the day of
the experiments. Frozen tissue segments were cut into 10 µm
thick sections, placed on glass slides and stained with 0.1%
Toluidine Blue (3 min) for perivascular mast cell detection.
Sections were coverslipped and light microscopy images were
taken (Nikon Eclipse TE2000-S (inverted microscope), Nikon
DXM1200F (digital camera)).
Vascular Reactivity
The method used for isometric tension recording has been
described in full elsewhere [8,19]. Briefly, two parallel stainless
steel pins were introduced through the lumen of the vascular
segment: one was fixed to the bath wall, and the other
connected to a force transducer (Grass FTO3C; Quincy, Mass.,
USA); in turn, this was connected to a model 7D Grass
polygraph. For EFS experiments, segments were mounted
between two platinum electrodes 0.5 cm apart and connected
to a stimulator (Grass, model S44) modified to supply the
appropriate current strength. Segments were suspended in an
organ bath containing 5 mL of KHS at 37°C continuously
bubbled with a 95% O2 -5% CO2 mixture (pH 7.4). Some
experiments were performed in endothelium-denuded
segments to eliminate the main source of vasoactive
substances, including endothelial NO. This avoided possible
actions by different drugs on endothelial cells that could lead to
misinterpretation of results. Endothelium was removed by
gently rubbing the luminal surface of the segments with a thin
wooden stick. The segments were subjected to a tension of 0.5
g, which was readjusted every 15 min during a 90-min
equilibration period before drug administration. After this, the
vessels were exposed to 75 mmol/L KCl to check their
functional integrity. Endothelium removal did not alter the
contractions elicited by KCl. After a washout period, the
presence/absence of vascular endothelium was tested by the
ability of 10 µmol/L acetylcholine (ACh) to relax segments
precontracted with 1 µmol/L noradrenaline (NA).
Frequency-response curves to EFS (1, 2, 4, 8 and 16 Hz)
were performed. The parameters used for EFS were 200 mA,
0.3 ms, 1–16 Hz, for 30 s with an interval of 1 min between
each stimulus, the time required to recover basal tone. A
washout period of at least 1 h was necessary to avoid
desensitization between consecutive curves. Three successive
frequency-response curves separated by 1-hour intervals were
performed in every segment. EFS responses in the presence of
mast cell stabilizers ketotifen (1 µmol/L, 0.1 µmol/L or 10
nmol/L), or tranilast (1 mmol/L, 0.1 mmol/L or 10 µmol/L) were
performed to evaluate the possible effect of these drugs on the
neural control of vasomotor tone. To analyze a possible time-
dependent effect, either ketotifen or tranilast were added to the
bath for different incubation periods: 1, 2, and 3 h, before the
corresponding frequency-response curves. To evaluate
whether the EFS-induced contractile response had a neural
origin, the blocker for nerve impulse propagation tetrodotoxin
(TTX, 0.1 µmol/L) was added to the bath 30 min in advance.
Vasodilator response to ACh (0.1 nmol/L-10 µmol/L) was
tested in endothelium-intact arteries from all experimental
groups.
To determine the participation of NO in the EFS-induced
response in all experimental groups, 0.1 mmol/L N G-nitro-L-
arginine methyl ester (L-NAME), the unspecific nitric oxide
synthase (NOS) inhibitor, or 1 µmol/L 1400W, the specific
inducible NOS inhibitor, were added to the bath 30 min before
performing the frequency–response curve.
To determine the participation of adrenergic component of
sympathetic innervation on the EFS-induced response in
control and ketotifen- or tranilast-incubated segments, 1 µmol/L
phentolamine, an α-adrenoceptor antagonist, was added to the
bath 30 min before performing the frequency-response curve.
The method to deplete sympathetic innervation has been
used previously by our group in this artery [20]. Briefly, control,
and ketotifen-incubated endothelium-denuded mesenteric
segments were incubated at room temperature for 10 minutes
in KHS (NaHCO3 and NaH2PO4 were omitted, unbuffered
Mast Cell Stabilizers and Mesenteric Innervation
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solution) containing 0.02 mmol/L glutathione and 1.46 mmol/L
of the neurotoxin 6-hydroxydopamine (6-OHDA). The pH of this
solution was adjusted to 4.9 with 0.05 mmol/L NaOH and then
the solution was covered with paraffin oil. Subsequently, the
arteries were immersed in normal KHS and EFS-induced
contraction experiments were performed.
The vasoconstrictor response of exogenous NA (1 nmol/L-10
µmol/L), and the vasodilator response to the NO donor
diethylamine NONOate (DEA-NO, 0.1 nmol/L–0.1 mmol/L)
were tested in mesenteric segments from all experimental
groups. The possible participation of superoxide anions (O2.-) in
the vasodilator response to DEA-NO was tested by incubation
with 0.1 mmol/L of the O2. - scavenger tempol.
Histamine and noradrenaline release
To measure histamine and NA release, we used a Histamine
Enzyme Immunoassay kit (Spibio, Berlin) and a Noradrenaline
Research EIA (Labor Diagnostica Nord, Gmbh & Co., KG),
respectively. Endothelium-denuded segments from control,
ketotifen-incubated (0.1 µmo/L, 3 hours) or tranilast-incubated
(0.1 mmo/L, 3 hours) mesenteric arteries were preincubated in
5 mL of KHS at 37°C and continuously gassed with a 95%
O2-5% CO2 mixture (stabilization period). This was followed by
two washout periods of 10 min in a bath of 0.4 mL of KHS.
Then the medium was collected to measure basal histamine or
NA release. Next, the organ bath was refilled, and cumulative
EFS periods of 30 s at 1, 2, 4, 8 and 16 Hz at 1 min intervals
were applied. Afterwards, the medium was collected to
measure EFS-induced histamine or NA release. The assay
was performed following the manufacturer’s instructions.
Results were expressed as nmol Histamine /mL mg tissue or
ng NA/mL mg tissue.
Nitric Oxide Release
Nitric oxide release was determined using the fluorescent
probe 4,5-diaminofluorescein (DAF-2), as previously described
[21]. Briefly, endothelium-denuded arteries were divided into
several experimental groups: control, and segments incubated
with ketotifen (0.1 µmol/L, 3 hours), tranilast (0.1 mmol/L, 3
hours), loratadine (1 µmol/L, 30 min) or famotidine (1 µmol/L,
30 min). After an equilibration period of 60 min in HEPES buffer
(in mmol/L: NaCl 119; HEPES 20; CaCl2 1.2; KCl 4.6; MgSO4
1; KH2PO4 0.4; NaHCO3 5; glucose 5.5; Na2HPO4 0.15; pH 7.4)
at 37°C, arteries were incubated with 2 µmol/L DAF-2 for 45
min. Then the medium was collected to measure basal NO
release. Once the organ bath was refilled, cumulative EFS
periods of 30 s at 1, 2, 4, 8 and 16 Hz at 1 min intervals were
applied. The fluorescence of the medium was measured at
room temperature using a spectrofluorimeter (LS50
PerkinElmer Instruments, FL WINLAB Software) with excitation
wavelength set at 492 nm and emission wavelength at 515 nm.
The EFS-induced NO release was calculated by subtracting
basal NO release from that evoked by EFS. Also, blank
samples were collected in the same way from segment-free
medium in order to subtract background emission. Some
assays were performed in the presence of 0.1 µmol//L TTX, 0.1
mmol/L L-NAME or 0.1 mmol/L 7-NI, a specific nNOS inhibitor,
to ensure the specificity of the method. The amount of NO
released was expressed as arbitrary units/mg tissue.
nNOs and P-nNOS expression
Western blot analysis of nNOS and phosphorylated nNOS
(P–NOS) expression was performed as previously described
[22,23]. Rabbit polyclonal antibody against nNOS (1:1000
dilution, Abcam), rabbit polyclonal antibody against P-nNOS
(1:1000 dilution, Abcam), and monoclonal anti-β-actin-
peroxidase antibody (1:50000, Sigma-Aldrich, Spain) were
used. Rat brain homogenates were used as a positive control.
Detection of O2-
O2- levels were measured using lucigenin
chemiluminescence, as previously described [22,24]. Briefly,
endothelium-denuded segments of control, ketotifen-incubated
(0.1 µmo/L, 3 hours) or tranilast-incubated (0.1 mmo/L, 3
hours) mesenteric arteries were equilibrated for 30 min in
HEPES buffer at 37°C, transferred to test tubes that contained
1 mL HEPES buffer (pH 7.4) containing lucigenin (5 µmol/L)
and then kept at 37 °C. The luminometer was set to report
arbitrary units of emitted light; repeated measurements were
collected during 5 min at 10 s intervals and averaged. 4,5-
Dihydroxy-1,3-benzene-disulphonic acid ‘‘Tiron’’ (10 mmol/L), a
cell permeant, non-enzymatic O2- scavenger-, was added to
quench the O2--dependent chemiluminescence. Some
segments were preincubated with 0.1 mmol/L tempol before
the experimental protocol was performed, in order to ensure
the specificity of the method. Also, blank measures were
collected in the same way without mesenteric segments to
subtract background emission.
3-nitrotyrosine (3-NT) detection
3-NT levels were determined using the Nitrotyrosine ELISA
kit from Abcam (Cambridge, UK). For this assay, frozen
endothelium-denuded segments of control, ketotifen-incubated
(0.1 µmo/L, 3 hours) or tranilast-incubated (0.1 mmo/L, 3
hours) mesenteric arteries were homogenized in PBS and
centrifuged at 600g for 10 min at 4°C. The supernatant was
then collected and used for the assay. 3-NT was measured
following the manufacturer’s protocol. Results were normalized
with protein content, using a DC protein assay kit (Bio-Rad
Laboratories, Hercules, CA, USA). Results are expressed as
ng 3-NT/mg protein.
Drugs used
L-NA hydrochloride, 6-hydroxydopamine (6-OHDA), ACh
chloride, diethylamine NONOate diethylammonium salt, TTX,
1400W, L -NAME hydrochloride, 7- nitroindazole, tempol,
phentolamine, DAF-2, lucigenin and tiron were purchased from
Sigma-Aldrich (Spain). Stock solutions (10 mmol/L) of drugs
were made in distilled water, except for NA, which was
dissolved in NaCl (0.9%)-ascorbic acid (0.01% w/v), and 7NI
and tempol, which were dissolved in DMSO. These solutions
were kept at -20°C and appropriate dilutions were made in
KHS on the day of the experiment.
Mast Cell Stabilizers and Mesenteric Innervation
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Data Analysis
The responses elicited by EFS or NA were expressed as a
percentage of the initial contraction elicited by 75 mmol/L KCl
for comparison between control, ketotifen-incubated and
tranilast-incubated segments. The relaxation induced by DEA-
NO was expressed as a percentage of the initial contraction
elicited by NA (Control: 995.5 + 14.6 mg; ketotifen: 1002.9 +
29.41 mg; tranilast: 946.7 + 28.47 mg, P> 0.05). Results are
given as mean + S.E.M. Statistical analysis was done by
comparing the curve obtained in the presence of the different
substances with the previous or control curve by means of
repeated measure analysis of variance (ANOVA) followed by
the Bonferroni post-hoc test. Some results were expressed as
differences of area under the curve (dAUC). AUC were
calculated from the individual frequency-response plots. For
dAUC, histamine, NO and NA release experiments, the
statistical analysis was done using one-way ANOVA followed
by Newman-Keuls post-hoc test. P< 0.05 was considered
significant.
Results
Perivascular mast cell detection
Mast cells were detected in the adventitial layer of
mesenteric arteries using toluidine blue staining (Figure 1).
Histamine release
Basal histamine release was significantly lower in ketotifen-
incubated and tranilast-incubated segments than in control
arteries. EFS increased histamine release in all experimental
groups, but the increase was greater in control segments.
Preincubation with TTX abolished EFS-induced histamine
release in all experimental conditions (Table 1).
Figure 1.  Mast cell localization by toluidine blue
staining.  Figure is representative of preparations from four
rats. Magnification: 400·X and 600 X.
doi: 10.1371/journal.pone.0073232.g001
Vasomotor Response to KCl
In endothelium-intact mesenteric segments, the
vasoconstrictor response to 75 mmol/l KCl was similar in all
experimental groups (Control, 964.3 ± 59.9 mg, 0.1 µmol/L
ketotifen, 913.6 ± 74.5 mg, 0.1 mmol/L tranilast ; 917.8 ± 65.2
mg; P > 0.05; n= 10 each group). Endothelium removal did not
alter KCl-induced vasoconstriction (Control, 976.3 ± 67.6 mg,
0.1 µmol/L ketotifen, 912.8 ± 62.7 mg, 0.1 mmol/L tranilast ;
915.5 ± 54.4 mg; P > 0.05; n= 10 each group).
Vascular responses to EFS
The application of EFS induced a frequency-dependent
contractile response in endothelium-intact mesenteric
segments. Four consecutive EFS curves were performed at 1-h
intervals in control mesenteric segments, and induced similar
contractions (Figure 2A). Preincubation with 10 nmol/L
ketotifen did not modify EFS-induced contractions, while
preincubation with 0.1 µmol/L or 1 µmol/L ketotifen for 1, 2 and
3 hours increased the contraction induced by EFS to a similar
extent (Figure 2B–2D). Preincubation with 0.1 mmol/L or 1
mmol/L tranilast for 1 or 2 hours induced a progressive
decrease in EFS-induced contractions that was stabilised after
3 hours. Preincubation with 10 µmol/L tranilast did not modify
EFS-induced contractions (Figure 2E–2G). For this reason, we
performed the following experiments preincubating with either
0.1 µmol/L ketotifen or 0.1 mmol/L tranilast during 3 hours.
Endothelium removal increased EFS-induced contractile
response similarly in segments from all experimental groups
(Figure 3A–3C). EFS-induced contractions were practically
abolished in segments from all experimental groups by the
blocker for nerve impulse propagation, TTX (0.1 µmol/L; table
2).
Vasodilator response to ACh
The vasodilator response to ACh was similar in all
experimental groups (Figure 3D, table 3).
Effect of ketotifen or tranilast on the nitrergic
component of vascular responses to EFS
Basal NO release was higher in control than in ketotifen- or
tranilast-incubated mesenteric segments (Figure 4A). EFS
Table 1. Effect of 0.1 µmol/L ketotifen and 0.1 mmol/L
tranilast on basal and EFS-induced histamine and NA
release.
 Histamine release NA release
 Basal EFS Basal EFS
Control 0.51 + 0.15 1.19 + 0.27* 6.65 + 0.99 9.25 + 1.13*
Ketotifen 0.15 + 0.03# 0.38 + 0.16*# 6.67 + 0.60 9.33 + 0.88*
Tranilast 0.19 + 0.02# 0.52 + 0.11*# 6.55 + 0.65 8.89 + 1.05*
TTX 0.58 + 0.09 0.66 + 0.17# 6.37 + 0.74 6.45 + 0.87#
This table presents histamine and NA levels released in basal and EFS conditions.
Results (means + SEM) are expressed as nmol histamine /mL mg tissue, or ng
NA/mL mg tissue. *P< 0.05 vs basal conditions. #P< 0.05 vs control. n= 6 animals
each group.
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increased NO release in all experimental groups, but the
increase was greater in control arteries (Figure 4A).
Preincubation with L-NAME (0.1 mmol/L), 7NI (0.1 mmol/L) or
TTX (0.1 µmol/L) practically abolished EFS-induced NO
release in arteries from either treatment group (table 4).
Additionally, preincubation with either the H1 receptor
antagonist loratadine (1 µmol/L) or the H2 receptor antagonist
famotidine (1 µmol/L) for 30 minutes did not modify basal or
EFS-induced NO release (table 4).
The expression of nNOS was not modified by incubation with
either ketotifen or tranilast (Figure 4B). P-nNOS expression
was decreased in homogenates from ketotifen- or tranilast-
incubated arteries compared to expression in control segment
homogenates (Figure 4B).
In NA-precontracted mesenteric segments (Control: 995.5 +
14.6 mg; ketotifen: 1002.9 + 29.41 mg; tranilast: 946.7 + 28.47
mg), DEA-NO (0.1 nmol/L–0.1 mmol/L) induced a
concentration-dependent relaxation that was greater in
segments preincubated with either mast cell stabilizer than in
control segments (Figure 4C, table 5). The O2- scavenger
tempol increased vasodilator response to DEA-NO in control
segments, but not in ketotifen- or tranilast- incubated segments
(Figure 5, table 5). Additionally, after subtracting the lucigenin
chemiluminescence obtained in the presence of tiron from that
obtained in its absence, the calculated tiron-quenchable
chemoluminescence was significantly lower in ketotifen-
incubated and tranilast-incubated segments than in control
Figure 2.  Vasoconstrictor response to EFS.  (A) Isometric
tension recording of the frequency-dependent contractions in
intact mesenteric artery segments from Wistar rats. Effect of
preincubation with 10 nmol ketotifen (B), 1 µmol/L ketotifen (C),
0.1 µmol/L ketotifen (D), 10 µmol/L tranilast (E), 0.1 mmol/L
tranilast (F) or 1 mmol/L tranilast (G) for 1, 2 and 3 hours on
frequency dependent contraction in mesenteric segments from
Wistar rats. Results (means ± S.E.M.) are expressed as a
percentage of tone induced by 75 mmol/L KCl. n= 10 animals
each group.
doi: 10.1371/journal.pone.0073232.g002
mesenteric segments. Preincubation of segments with tempol
strongly decreased the tiron-quenchable chemiluminescence
(Table 6). Additionally, 3-NT levels were decreased in
Figure 3.  Endothelium influence on vasoconstrictor
response to EFS.  Effect of endothelium removal on the
vasoconstrictor response to electrical field stimulation in control
(A), ketotifen-incubated (B) or tranilast-incubated (C)
mesenteric segments from Wistar rats. Results (means ±
S.E.M.) are expressed as a percentage of tone induced by 75
mmol/L KCl. n= 10 animals each group. Insert graph shows
differences of area under the curve (dAUC) in the absence or
presence of 01 μmol/L phentolamine, expressed as arbitrary
units. * P< 0.05 control vs. tranilast. (D) ACh-induced
vasodilation in endothelium-intact control, ketotifen-incubated
or tranilast-incubated mesenteric segments. Results (mean +
S.E.M.) were expressed as a percentage of the previous tone
elicited by exogenous NA. n = 6 animals each group.
doi: 10.1371/journal.pone.0073232.g003
Table 2. Effect of preincubation with tetrodotoxin (TTX, 0.1
µmol/L) or 6-hydroxydopamine (6-OHDA, 1.46 mmol/L) on
the frequency–contraction curves performed in control,
ketotifen-incubated (0.1 µmol/L) and tranilast-incubated (0.1
mmol/L) mesenteric segments.
 1 Hz 2 Hz 4 Hz 8 Hz 16 Hz
Control 9.2 + 1.7 27.6 + 3.5 45.9 + 3.4 62.6 + 3.3 79.1 + 3.7
TTX 0 0 0 0.5 + 0.04 0.9 + 0.2
6-OHDA 0 0 0.1 + 0.03 0.2 + 0.05 0.4 + 0.1
Ketotifen 17.8 + 1.7 34.9 + 4.1 53.5 + 4.8 69.6 + 3.8 90.1 + 2.6
TTX 0 0 0 0.2 + 0.01 0.6 + 0.1
6-OHDA 0 0 0.2 + 0.06 0.5 + 0.1 0.9 + 0.2
Tranilast 2.5 + 1.1 7.0 + 3.1 21.3 + 6.1 39.9 + 8.2 61.5 + 8.7
TTX 0 0 0 0 0.1 + 0.01
Results (means ± S.E.M.) are expressed as percentages of the response elicited
by 75 mM KCl; zeros are used when contraction was not detected. n = 5–7
animals.
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ketotifen-incubated and tranilast-incubated segments (In ng 3-
NT/mg protein: Controla: 1.71 + 0.31; 0.1 µmol/L ketotifenb:
0.92 + 0.06; 0.1 mmol/L tranilastc: 0.98 + 0.11; a-b, a-c P< 0.05; n
= 6 animals each group).
In line with these results, the contraction induced by EFS
was significantly increased by preincubation with the unspecific
NOS inhibitor L-NAME (0.1 mmol/L) in control segments, but it
did not have any effect in either ketotifen- or tranilast-treated
segments (Figure 6). The specific iNOS inhibitor 1400W did not
Table 3. Emax and log EC50 values of vasodilator responses
to ACh in control, ketotifen-incubated (0.1 μmo/L) or
tranilast-incubated (0.1 mmol/L) mesenteric arteries from
Wistar rats.
 Emax log EC50
Control 91.88 + 2.62 -6.98 + 0.09
Ketotifen 97.22 + 3.83 -7.07 + 0.13
Tranilast 90.64 + 3.68 -7.02 + 0.15
Results are expressed as means + S.E.M. n=6 animals each group.
Figure 4.  Effect of ketotifen and tranilast on neuronal NO
synthesis and vasodilation (A) Effect of preincubation with
ketotifen or tranilast on basal and EFS-induced NO release
in mesenteric segments.  n = 5 animals each group. Results
(means + S.E.M.) are expressed as arbitrary units (A.U.)/mg
tissue.
*P< 0.05 vs basal; # P< 0.05 vs control. (B) Western blot for
nNOS and P-nNOS expression in control, ketotifen- and
tranilast-incubated mesenteric segments. Figure is
representative of preparations from six samples in each group.
Lower panel shows relation between densitometric analyses for
P-nNOS vs. nNOS expression. * P< 0.05. (C) Vasodilator
response to DEA-NO in control, ketotifen- incubated and
tranilast-incubated mesenteric segments. Results (means +
S.E.M.) are expressed as a percentage of the inhibition of
contraction induced by NA. n = 6 animals each group.
doi: 10.1371/journal.pone.0073232.g004
modify EFS-induced contraction in any experimental group
(Figure 6).
Effect of preincubation with ketotifen or tranilast on
sympathetic innervation
Preincubation with 0.1 µmol/L ketotifen did not modify the NA
contractile response (0.1 nmol/L–10 µmol/L) (Figure 7A), while
the response was decreased in 0.1 mmol/L tranilast-
preincubated segments (Figure 7A). Both basal and EFS-
induced NA releases were not modified by preincubation with
either 0.1 µmol/L ketotifen or 0.1 mmol/L tranilast (Table 1).
The contraction elicited by EFS was significantly reduced by
the α-adrenoceptor antagonist, phentolamine (1 µmol/L), in
segments from control, ketotifen-incubated and tranilast-
incubated segments. The decrease was lower in tranilast-
incubated than in control mesenteric segments (Figure 7B–7D).
Preincubation with 6-OHDA practically abolished the EFS-
Table 4. Effect of preincubation with L-NAME (0.1 mmol/L),
7-nitroindazol (7-NI, 0.1 mmol/L), loratadine 7-NI, 1 mmol/L
loratadine, 1 mmol/L famotidine or 0.1 mmol/L TTX on
basal and EFS-induced NO release in control, ketotifen-
incubated (0.1 mmol/L) and tranilast-incubated (0.1 mmol/L)
mesenteric segments.
 Basal EFS
Control 0.28 + 0.05 0.95 + 0.09*
L-NAME 0.26 + 0.04 0.29 + 0.07#
7-NI 0.27 + 0.09 0.31 + 0.06#
Loratadine 0.32 + 0.07 0.92 + 0.13*
Famotidine 0.27 + 0.12 0.94 + 0.17*
TTX 0.25 + 0.03 0.28 + 0.11#
Ketotifen 0.07 + 0.01 0.23 + 0.11*
L-NAME 0.05 + 0.03 0.07 + 0.04#
7-NI 0.09 + 0.04 0.11 + 0.04#
TTX 0.06 + 0.03 0.07 + 0.03#
Tranilast 0.07 + 0.02 0.38 + 0.16*
L-NAME 0.06 + 0.01 0.09 + 0.04#
7-NI 0.06 + 0.02 0.08 + 0.03#
TTX 0.04 + 0.01 0.04 + 0.01#
Results (means ± S.E.M.) are expressed in arbitrary units (A.U.)/mg tissue. n =
6-10 animals each group. *P < 0.05 compared with the respective basal NO
release. #P < 0.05 compared with conditions without specific inhibitor.
Table 5. Emax and log EC50 values of vasodilator responses
to DEA-NO in control, ketotifen-incubated (0.1 µmol/L) or
tranilast-incubated
 Untreated Tempol-treated
 Emax log EC50 Emax log EC50
Control 101.5 + 2.16 -5.39 + 0.04 94.76 + 7.52 -6.10 + 0.18#
Ketotifen 99.11 + 8.40 -6.14 + 0.18* 101.10 + 2.38 -5.95 + 0.15
Tranilast 98.02 + 2.44 -6.33 + 0.07* 98.62 + 3.03 -6.38 + 0.08
Results are expressed as means + S.E.M. n= 6 animals each group. *P < 0.05 vs.
control segments. #P< 0.05 tempol incubated vs. unincubated segments.
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induced contraction in segments from control and ketotifen-
incubated mesenteric segments (Table 2).
Discussion
The results of the present study demonstrate for the first time
that the mast cell stabilizers ketotifen and tranilast modify EFS-
induced vasoconstriction differently in rat mesenteric arteries.
Ketotifen increased EFS-induced vasoconstriction, an effect
that seems to be mediated at least by a decrease in neuronal
NO release, while tranilast, although also decreasing neuronal
NO release, diminished EFS-induced contraction through a
decreased vasoconstrictor response to NA. The effect of these
drugs on neuronal NO release is mediated by a decrease in
nNOS phosphorylation.
Figure 5.  Effect of superoxide anions on NO-dependent
vasodilation.  Effect of 0.1 mmol/L tempol on the
concentration–response curves to DEA-NO in control (A)
ketotifen-incubated (B) and tranilast-incubated (C)
mesenteric segments.
Results (means + S.E.M.) are expressed as a percentage of
the inhibition of the contraction induced by NA. n=6 animals
each group.
doi: 10.1371/journal.pone.0073232.g005
Table 6. Effect of 0.1 µmol/L ketotifen or 0.1 mmol/L
tranilast on O2. - release. Effect of preincubation with 0.1
mmol/L tempol on O2. - release in control, ketotifen-
incubated and tranilast-incubated mesenteric segments.
 Untreated Tempol-treated
Control 103.4 + 8.2 5.4 + 1.3#
Ketotifen 54.2 + 1.6* 2.1 + 1.8#
Tranilast 39.1 + 2.8* 3.1 + 1.0#
Results (means + S.E.M.) are expressed in chemoluminescence units/ min mg
tissue. *P < 0.05 compared with control group. #P < 0.05 compared with conditions
without tempol. n= 6-10 animals each group.
The remarkable connection between innervation and mast
cells has attracted much interest. This aspect has been widely
studied in the abdominal cavity, where mast cell activation
modulates various gastrointestinal functions [9,25–28]. In the
current study, we have observed that mast cells are located in
the adventitial layer, and that histamine is released under basal
conditions indicating, that perivascular mast cells are tonically
activated. Neurotransmitter release has been described to alter
mast cell activation and their release of multiple mediators,
including histamine [11,12]. In the current study, histamine
release was enhanced by EFS. The fact that preincubation with
TTX abolishes EFS-induced histamine release reveals for the
first time that neurotransmitter release from mesenteric artery
innervation activates mast cell degranulation. Both basal and
EFS-induced histamine release were decreased by ketotifen or
tranilast incubation, confirming the stabilizing role of these
drugs.
The interplay of mast cells with perivascular neuronal
function and the possible functional consequences are highly
interesting when examining aspects of hemodynamic changes
when mast cells are stabilized. Thus, the current study was
designed to analyze the effect of mast cell stabilization on
perivascular innervationfunction. For this purpose, we studied
the effect of ketotifen and tranilast on the vasomotor response
produced by EFS in rat superior mesenteric arteries.
We first analyzed whether ketotifen and tranilast modified the
EFS-induced contraction observed in mesenteric segments. As
we showed in the Results section, after performing a time-
course pilot study, we considered it appropriate to perform
experiments with either 0.1 µmol/L ketotifen or 0.1 mmol/L
tranilast for 3 hours. EFS produced a frequency-dependent
Figure 6.  Effect of ketotifen or tranilast on nitrergic
innervation function.  Effect of preincubation with 0.1 mmol/L
L-NAME or 1 µmol/L 1400W on the frequency-response curves
in control (A) ketotifen-incubated (B) or tranilast-incubated (C)
mesenteric segments. Results (means + S.E.M.) are expressed
as a percentage of tone induced by 75 mmol/L KCl. n = 6
animals each group.
doi: 10.1371/journal.pone.0073232.g006
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contraction in endothelium-intact mesenteric segments from all
the experimental groups as reported in previous reports by our
group [22,23,29,30]. We observed that ketotifen and tranilast
had opposite effects: while preincubation with ketotifen
increased the contraction induced by EFS, tranilast decreased
that contraction. These modifications were not attributable to
changes in the intrinsic contractile machinery as was
demonstrated by the similar vasoconstrictor response to KCl in
all experimental groups. Endothelium removal increased
vasoconstrictor response to EFS to the same extent in the
three experimental groups, indicating that the modulating role
of endothelium is not modified by either ketotifen or tranilast.
The fact that ACh-induced vasodilation was not modified in any
experimental group reinforces this observation. Therefore,
these results indicate that the modifications observed after
preincubation with either ketotifen or tranilast are due to
modifications in perivascular innervation function, as was
confirmed by the abolishment of EFS-induced vasoconstriction
in the presence of TTX.
Superior mesenteric artery possesses different innervations,
mainly vasodilator nitrergic and vasoconstrictor sympathetic
innervations, which are implicated in the control of vascular
tone [6–8]. We analyzed the participation of each kind of
innervation in the vasoconstriction induced by EFS, and the
possible modifications in this participation that were induced by
either ketotifen or tranilast.
Figure 7.  Effect of ketotifen or tranilast on sympathetic
innervation function.  (A) Effect of preincubation with
ketotifen or tranilast on the vasocostrictor response curves to
noradrenaline. Effect of 0.1 µmol/L phentolamine on the
frequency-response curve in control (B), ketotifen-incubated
(C) or tranilast-incubated (D) segments. Results (means +
S.E.M.) are expressed as a percentage of tone induced by 75
mmol/L KCl.
n = 5-6 animals each group. Insert graph shows
differences of area under the curve (dAUC) in the absence
or presence of 01 μmol/L phentolamine, expressed as
arbitrary units. * P< 0.05 control vs. tranilast.
doi: 10.1371/journal.pone.0073232.g007
Ketotifen and tranilast have been reported to alter eNOS and
iNOS activity in several tissues [31–33]. However, to our
knowledge, there are no reports about possible alterations in
nNOS expression and/or activity in perivascular nerve endings.
Therefore, our next objective was to analyze the possible effect
of ketotifen and tranilast on neuronal NO release from nitrergic
nerve endings. Preincubation with ketotifen or tranilast
diminished both basal and EFS-induced NO release. The fact
that, in all cases, EFS-induced NO release was abolished by
preincubation with TTX, L-NAME, the non-specific NOS
inhibitor, or 7-nitroindazol (7-NI), the specific nNOS inhibitor,
confirms the neural origin of the NO release.
Besides its role as a mast cell membrane stabilizer, it has
been clearly demonstrated that ketotifen also possesses
powerful and sustained non-competitive histamine blocking
properties, as it antagonizes both the H1 and H2 histamine
receptors. The fact that neither the selective H1 antagonist
loratadine nor the selective H2 antagonist famotidine modified
either basal or EFS-induced NO release rules out the
participation of histamine receptors in this response.
NO released from nerve endings is biosynthesized by nNOS
[8,22,23,30]. Since preincubation with either ketotifen or
tranilast decreased both basal and EFS-induced NO release,
our next objective was to determine if these decreases
produced by ketotifen and tranilast were due to modifications in
nNOS expression and/or activity. We found that nNOS protein
expression was not modified. nNOS must be phosphorylated in
order to be activated. P-nNOS expression was decreased by
treatment with either ketotifen or tranilast. These results
indicate that the decreased NO release observed after
preincubation with either ketotifen or tranilast is due to a
decrease in nNOS activation. To our knowledge this is the first
study to demonstrate the actions of ketotifen and tranilast on
neuronal NO release from perivascular innervation in
mesenteric bed.
Previously, we have demonstrated in this rat strain that both
the non-selective NOS inhibitor L-NAME and the specific nNOS
inhibitor 7-NI decrease EFS-induced NO release to a similar
extent [30]. However, in vascular reactivity experiments,
preincubation with 7-NI also decreased vasoconstrictor
response to NA, making the analysis of EFS-induced
contractions very complex, and leading to result
misinterpretation [29,30]. For that reason, we used L-NAME in
vascular reactivity experiments. L-NAME did not modify EFS-
induced contractions in ketotifen or tranilast-incubated
segments, in contrast to the increase observed in control
segments, thus suggesting that both ketotifen and tranilast
decrease nitrergic innervation function. Preincubation with the
specific iNOS inhibitor 1400W did not modify vasoconstrictor
response to EFS, ruling out an iNOS participation in the effects
of ketotifen and tranilast.
Possible alterations in smooth muscle sensitivity to NO
cannot be ruled out. A decrease in O2- was observed in
ketotifen- and tranilast-incubated mesenteric segments, in
agreement with the previously described antioxidant effect of
both mast cell stabilizers [34,35]. Additionally, 3-NT detection,
used as a stable marker of peroxynitrite detection [36], showed
a marked decrease in segments preincubated with either
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ketotifen or tranilast. Therefore, both ketotifen and tranilast
could alter NO metabolism and bioavailability. The vasodilator
response to DEA-NO was increased by preincubation with
either ketotifen or tranilast. Preincubation with the O2-scavenger
tempol increased vasodilator response to DEA-NO in control
segments, but not in ketotifen or tranilast-incubated segments,
thus confirming a decreased NO metabolism through
decreased O2-release.
Therefore, ketotifen and tranilast induce two opposite effects:
a decrease in neuronal NO release, and an increase in NO
bioavailability due to a decrease in O2- formation. The net effect
is a decreased role for nitrergic innervation.
The fact that both ketotifen and tranilast exert the same
effect on neuronal NO release does not explain why they
produce opposite effects in the EFS-induced contractile
response. Therefore, different influences by ketotifen and
tranilast on the function of other innervations cannot be ruled
out. Given the principal role played by sympathetic innervation
in EFS-induced vasoconstriction [2,8], we analyzed the
possible influence of ketotifen and tranilast on EFS-induced
vasoconstriction. Vasoconstriction elicited by EFS was strongly
reduced by phentolamine in segments from all experimental
groups, indicating that this response was mediated mainly by
NA release from the adrenergic component of sympathetic
nerve terminals, with subsequent activation of α-adrenoceptors.
This decrease was similar in control and ketotifen-incubated
mesenteric segments. However, the decrease in EFS-induced
contraction obtained by preincubation with phentolamine was
lower in tranilast-preincubated segments, suggesting different
influences by ketotifen and tranilast on the adrenergic
component of sympathetic innervation. These differences could
be due to modifications in either NA release or vasoconstrictor
response to exogenous NA. When analysing NA release, we
observed that it was not modified by mast cell stabilization with
either ketotifen or tranilast. This result shows that the effect of
these drugs on EFS-induced vasoconstriction is not mediated
by changes in NA release. When concentration–response
curves to exogenous NA were performed, we observed that
ketotifen did not modify the vasoconstrictor response, while
tranilast decreased it. Taken together, these results confirm
that the adrenergic component of sympathetic innervation is
not affected by ketotifen in the mesenteric artery, as also
reported in other tissues [37]. However, although tranilast did
not affect NA release, it did reduce the contractile response, as
observed with other vasoconstrictor agents [18,38]. This effect
can be attributed to inhibition of the Ca2+ influx from the
extracellular environment and Ca2+ release from intracellular
Ca2+ stores, as previously reported [39,40]. The fact that
vasoconstriction produced by KCl remained unmodified in the
presence of tranilast suggests that this drug interferes with the
Ca2+ movement coupled to receptor activation, but not to the
movement induced by depolarization. This differential influence
on adrenergic innervation seems to be implicated in the
opposite results obtained when incubating with one mast cell
stabilizer or the other.
After preincubation with phentolamine, we observed a
remnant contractile response to EFS in control and ketotifen-
incubated segments, but not after tranilast treatment. This
result indicates that tranilast abolished the function of another
vasoconstrictor factor. The depletion of sympathetic innervation
in control and ketotifen treated segments by preincubation with
the neurotoxin 6-OHDA abolished the remant vasoconstriction,
thereby confirming that this contractile neurotransmitter has a
sympathetic origin in control and ketotifen-incubated segments.
This neurotransmitter could probably be ATP, as we have
previously observed in other experimental conditions [21,30].
Taken together, these results indicate that both ketotifen and
tranilast alter the vasoconstrictor response to EFS in rat
mesenteric artery, but in an opposite manner: ketotifen
increases EFS-induced contraction, while tranilast decreases it.
This fact is due to different actions by these drugs on the
sympathetic and nitrergic innervations: both ketotifen and
tranilast diminish nitrergic innervation function through a
decrease in nNOS activation, while tranilast also decreases
sympathetic innervation function, mainly through decreased NA
vasoconstriction. These results indicate that the election of the
mast cell stabilizer could be relevant, since it could induce
important hemodynamic changes.
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